Belpointe Asset Management’s Profound Medical PROF Stock Holding History

Belpointe Asset Management’s Portfolio PROF Stock Details PROF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-186	Closed	-$1.73K	–	2631
2023 Q1	$1.73K	Hold	186	–	–	﹤0.01%	3346
2022 Q4	$2.03K	Buy	+186	New	+$1.01K	﹤0.01%	3261

Other funds holding PROF

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

LBA

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return

TIM

Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return

Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ZDA

Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return

Belpointe Asset Management's PROF Position: Q2 2023 in Review

Belpointe Asset Management sold out of Profound Medical (PROF) in Q2 2023, closing a stake of 186 shares — an estimated $1.73K sold.

Belpointe Asset Management first reported a position in PROF in Q4 2022 and held it in 2 quarters. The position peaked at $2.03K in Q4 2022. 33 funds tracked by Wall St. Rank hold PROF as of Q2 2023.

Belpointe Asset Management reported no remaining Profound Medical position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 186 Profound Medical shares in Q2 2023, an estimated $1.73K.
Belpointe Asset Management first reported a position in Profound Medical in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Profound Medical position peaked at $2.03K in Q4 2022.
33 funds tracked by Wall St. Rank held Profound Medical as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.